Form D · Biotechnology

Carna Inc.

Boston, MA · CIK 0002055006

Offering snapshot reported Jun 11, 2026 · SEC filing

Reported sold: $9.07M
Investors reported: 27
Minimum accepted: $0
First sale: Jan 3, 2025

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$3,400,000 → $9,073,160
Reported investors13 → 27
Minimum accepted$50,000 → $0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 11, 2026	Amendment	$9,073,160	$5,673,160vs Feb 5, 2025	27	SEC filing
Feb 5, 2025	Initial	$3,400,000	No comparison	13	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-537386

Amounts above do not include $1,167,500 in Simple Agreements for Future Equity converted upon the initial closing of the Offering.

Source: Form D, filed Jun 11, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Boris Berat	Director, Executive, Promoter
Thomas Dolan	Executive
Michelle Longmire	Director
Juan Marichal	Promoter
Justin Nguyen	Executive
Jose Pereyra	Director, Promoter
Faisal Rusho	Executive
Mary Sallah	Executive
Salvatore Viscomi	Director, Executive, Promoter
David Vogel	Promoter

Issuer details

Industry: Biotechnology (See others in industry)

Address:

200 Newbury Street Suite 401
Boston, MA, 02116